13 card poker game

13 card poker game What people read on Wikipedia in 2024Metropolitan Stock Exchange has raised ₹238 crore through issuance of equity share on a private placement to a group of investors including promoters of Groww and Zerodha. The board of the exchange in a meeting held on Tuesday said it has allotted 119 crore equity share of ₹1 at a premium of ₹1 to clutch of investors. Subsequently, shares will be issued to prominent investors such as Billionbrains Garage Ventures, which owns tech-driven broking firm Groww, Rainmatter Investments promoted by Zerodha’s Nithin Kamath and Kailash Nadh, Securicorp Securities India and Share India Securities. The allocation of shares will be subject to approval by members of the company at the ensuing extra ordinary general meeting, said the exchange. The exchange intends to use the fund raised to strengthen technological infrastructure, expand its market presence and operations, improve liquidity and trading volumes and launch new products and services tailored to Indian and global investors. Incidentally, discount broking firm Zerodha promoters booked profit on their investment in BSE in the June quarter. Zerodha reduced its stake in BSE from 23.3 lakh shares (1.72 per cent) in the March quarter to 19.8 lakh (1.46 per cent) in the June quarter. This reduction follows BSE’s exceptional performance rallying 140 per cent in last one year to ₹5,541 a piece against ₹2,311 logged on December 26, 2023 and in last three months it was up 44 per cent while it jumped 23 per cent in one month. Zerodha’s stake in BSE was valued at about ₹563 crore. The total valuation of Zerodha’s portfolio in listed stocks was ₹1,536 crore. Meanwhile, the Kamath brothers, founders of Zerodha, have an estimated net worth of ₹41,000 crore, according to the Hurun India Rich List 2024. Comments

Bill Shorten represents the best in Australian politics. And the worst. In his valedictory speech to the House on Thursday, ending 17 years in parliament, he spoke of the achievement in government that was “closest to my heart” – the National Disability Insurance Scheme. “The NDIS belongs alongside Medicare and superannuation as examples of Australian exceptionalism.” Illustration by Simon Letch Credit: Shorten is rightly proud of the NDIS. It was a world-first undertaking and instantly set the standard for the way that civilised societies should treat their disabled citizens. It was not all his work. As Shorten acknowledged, it was Kevin Rudd who gave him his start in the field by appointing him as the parliamentary secretary for disabilities in 2007. “I thought I knew hardship, having seen disadvantage representing workers,” Shorten told the House. “But nothing had prepared me for the way literally hundreds of thousands of Australians with disability and their carers were sentenced to a second-class life of lesser opportunity.” And it was Julia Gillard who committed her government to implementing it. Shorten recalls asking the then prime minister to do just one thing: “I asked her to meet five people in my office and leave her phone outside for an hour and a half.” She heard their stories and was persuaded. Credit must also go to Tony Abbott, the opposition leader who embraced the idea. As he said: “Normally I’m Mr No, but on this occasion I’m Mr Yes!” It’s hard for any major reform to endure without bipartisan support; Abbott gave it that support. Bill Shorten delivers his valedictory speech in the House of Representatives on Thursday. Credit: Dominic Lorrimer But Shorten can take most of the credit for creating the scheme when Labor was in power in 2007-2013, and for repairing it now that Labor is in power once more. By the time Anthony Albanese gave Shorten responsibility for the NDIS in 2022, it had veered out of control. It had become an open secret that it was rife with rorting. Not rorted by the disabled people receiving help, but by the companies and individuals who were supposed to help them and who then billed the government for services provided.Three takeaways from UL's road victory over ULM Warhawks for 10th win of season

NoneIndia’s start-up funding in 2024 showcased resilience and maturity as consolidation was seen in the sector, where the funding ecosystem matured beyond hype cycles, embracing sustainability and profitability as key drivers of investment decisions. “Year 2024 was all about consolidation... not hyped nor underhyped, but a steady year for the ecosystem,” said Dipanjan Basu, co-founder of Bengaluru-based Fireside Ventures. Start-ups raised $10.3 billion this calendar until November 30, slightly more than $9.6 billion raised during the same period of 2023, data from Venture Intelligence showed. The number of deals closed so far this year fell to 809 from 829 a year back. For context, venture start-ups in the country raised $24 billion in 2022 while in the go-go period of 2021, local start-ups had mopped up $36 billion. Early-stage investments this year remained at the same level as 2023 at $1.6 billion, while growth-stage deals increased to $5.2 billion from $4.9 billion. “In the early-stage eco-system, there has been an explosion in the number of ideas and pitch decks,” Ninad Karpe, Founder & Partner, 100X.VC. This has been fuelled by the growing number of entrepreneurs leaving stable jobs to launch new ventures, coupled with increasing participation from angel investors and micro VCs. However, this influx of capital has introduced some frothiness, as access to funding has become more accessible, leading to inflated valuations for some start-ups. While early-stage funding has flourished, mid-stage funding remains a significant challenge. There is a noticeable gap in the availability of capital for start-ups between Series A to Series C rounds. Vikram Ramasubramanian, Partner, Inflection Point Ventures, points out, “There is a gap in mid-stage funding... but debt financing has emerged as an option to help businesses grow.” The lack of sufficient mid-stage investment has forced many start-ups to look at alternative financing options like debt funding to bridge the gap. Late-stage investments this year saw $3,945-million investment across 74 rounds. The rate of unicorn addition accelerated in 2024 compared to last year – with start-ups like Rapido, Ather Energy, Moneyview, Perfios and Krutrim raising funds over $1 billion. In 2024, AI, fintech and health tech emerged as dominant sectors, driven by their scalability and critical impact. Meanwhile, deep tech and space tech were the new frontrunners. “These sectors, once considered niche, are now redefining the boundaries of innovation,” noted Ninad from 100x.VC. Space tech, in particular, has gained traction, bolstered by advancements in technology and government support. “Government initiatives have simplified procurement processes, enabling young entrepreneurs to focus on building scalable businesses,” said Ramasubramanian. The year 2024 emerged as a defining period for start-up exits, with significant momentum across IPOs, strategic acquisitions and secondary market transactions. Several high-profile IPOs captured the spotlight, signalling a growing appetite for public-market-ready start-ups. Swiggy IPO, in particular, demonstrated that consumer-tech companies can thrive in public markets, bolstering investor confidence. “Swiggy IPO and others have driven public-market confidence, signalling a new era for start-ups,” said Basu of Fireside Ventures. Industry analysts believe these moves could open doors for other start-ups in traditionally-underrepresented segments. “The IPOs we’ve seen this year are proof that the public markets are ready to embrace a diverse range of start-ups, provided they showcase strong fundamentals and a clear path to profitability,” added Ramasubramanian. Secondary markets also played a crucial role, offering liquidity to early investors and founders. With tighter valuations and disciplined investing, secondary transactions became an integral part of the start-up lifecycle. As the ecosystem stabilises, the focus will likely shift toward a more disciplined growth and sustainable business models. Experts predict a continuation of trends such as M&A activity, growth-stage funding and further development in sectors like AI, logistics, and agritech. “2024 has taught founders the importance of scalability and sustainability. These lessons will be invaluable as we move into 2025,” noted Karpe. Despite challenges like tighter valuations and a cautious mid-stage funding environment, the overall sentiment for 2025 is optimistic. With a wealth of dry powder yet to be deployed, investors and entrepreneurs alike are gearing up for another robust year in India’s dynamic start-up ecosystem. Comments

Nexgel director Jerome Zeldis buys common stock worth $9,999

SAN DIEGO, Dec. 03, 2024 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases, today announced that on December 2, 2024 the Company granted restricted stock units (RSUs) representing 18,600 shares of its common stock to one newly-hired non-executive employee. The grant was approved by the Compensation Committee of the Company’s Board of Directors and granted under the Company’s Amended and Restated Inducement Equity Plan as an inducement material to the new employee entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4). The RSUs will vest over four years, with 25% of the shares underlying each RSU award vesting on each anniversary of the grant date, subject to the employee being continuously employed by the Company through each vesting date. About Fate Therapeutics, Inc. Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases. Using its proprietary iPSC product platform, the Company has established a leadership position in creating multiplexed-engineered iPSC lines and in the manufacture and clinical development of off-the-shelf, iPSC-derived cell products. The Company’s pipeline includes iPSC-derived natural killer (NK) cell and T-cell product candidates, which are selectively designed, incorporate novel synthetic controls of cell function, and are intended to deliver multiple therapeutic mechanisms to patients. Fate Therapeutics is headquartered in San Diego, CA. For more information, please visit www.fatetherapeutics.com . Contact: Christina Tartaglia Precision AQ 212.362.1200 christina.tartaglia@precisionaq.com